Skip to main content

Advertisement

Table 1 Characteristics of core strategy

From: Contribution of antimicrobial stewardship programs to reduction of antimicrobial therapy costs in community hospital with 429 Beds --before-after comparative two-year trial in Japan

Category n = 1427
Status of antimicrobial use n (%) 573 (40.2)
Carbapenems use 288 (20.2)
3,4-Generation Cephalosporins, Quinolones 149 (10.4)
>14 inpatient days  
Glycopeptides use 136 (9.5)
Isolation of pathogenic microorganisms n (%) 854 (59.8)
Blood culture - positive 360 (25.2)
MRSA 334 (23.4)
ESBLs 73 (5.1)
P. aeruginosa 71 (5.0)
Acinetobacter baumannii 16 (1.1)
  1. MRSA: methicillin-resistant Staphylococcus aureus.
  2. ESBLs: extended spectrum beta-lactamase-producing organisms.
  3. P. aeruginosa: Pseudomonas aeruginosa resistant to at least one among Carbapenems, Quinolones and Aminoglycosides.